tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

TELA Bio Reports Q3 Revenue Growth and New Credit Facility

Story Highlights
  • TELA Bio reported a 9% revenue increase for Q3 2025, reaching $20.7 million.
  • The company secured a $70 million credit facility and revised its 2025 revenue growth forecast to at least 16%.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
TELA Bio Reports Q3 Revenue Growth and New Credit Facility

Meet Your ETF AI Analyst

An update from TELA Bio ( (TELA) ) is now available.

On November 13, 2025, TELA Bio reported its third-quarter financial results, highlighting a 9% revenue increase to $20.7 million compared to the same period in 2024. The company also announced a strengthened capital position through a $70 million credit facility with Perceptive Advisors, expanded its board, and accelerated hiring in its U.S. sales organization. Despite a net loss of $8.6 million, the results reflect strategic changes and leadership enhancements that are expected to support future growth. TELA Bio revised its full-year 2025 revenue guidance to at least 16% growth over 2024, demonstrating confidence in its operational strategies and market positioning.

The most recent analyst rating on (TELA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on TELA Bio stock, see the TELA Stock Forecast page.

Spark’s Take on TELA Stock

According to Spark, TipRanks’ AI Analyst, TELA is a Underperform.

TELA Bio’s overall stock score is primarily impacted by its financial performance and technical analysis. Despite revenue growth, the company faces significant profitability and cash flow challenges. Technical indicators show bearish momentum, and the negative P/E ratio suggests overvaluation. The positive aspects from the earnings call are overshadowed by these financial and technical difficulties.

To see Spark’s full report on TELA stock, click here.

More about TELA Bio

TELA Bio, Inc. is a commercial-stage medical technology company that specializes in innovative soft-tissue reconstruction solutions. The company focuses on optimizing clinical outcomes by preserving and restoring the patient’s own anatomy, providing surgeons with advanced and economically effective solutions that leverage natural healing responses while minimizing long-term exposure to synthetic materials.

Average Trading Volume: 96,454

Technical Sentiment Signal: Strong Sell

Current Market Cap: $45.16M

Learn more about TELA stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1